Radient Pharmaceuticals Corporation (RPC) is our first stock in this report.
An interesting article came out on RPC last week that ranked it #3. It points out a strong valuation comparison.
Top 10 Penny Stocks of 2010at TheStreet.com(Thu, Jun 17)
Developments in 2010: In early April, Radient said it entered into an exclusive five-year collaboration agreement with Jaiva Technologies to conduct clinical trials for Radient’s cancer therapy and vaccine technology in India. Radient said its monoclonal antibody test, which it began working on 20 years ago, “may change how people screen for early cancer detection.” The stock jumped to a 52-week high of $2.59 before Radient announced a dilutive financing deal, which dropped shares back down to $1. In May, Radient announced a collaboration agreement with Provista Life Sciences for its Onko-Sure cancer test.
Valuation: Radient’s news releases in April sparked a speculative trading frenzy, which came to a screeching halt when the company capitalized on the rapid increase in share price with the financing deal. The fear of another capital raising on another increase in share price will likely be on the minds of Radient investors. Looking at valuation, Radient offers value on a price-to-book (1.43) and a price-to-sales (2.96) basis, according to Bloomberg. That compares to the average of the pharmaceuticals and biotech sector (5.61 and 35.21, respectively).Keep in mind RPC is set to monitize on it’s breakthrough cancer screening tool.
Radient Pharmaceuticals Announces First Quarter 2010 Financial Results; Provides Update on Onko-Sure(TM) Product Sales and Monetization of Its China-Based Subsidiary Jade PharmaceuticalsMarketwire(Tue, May 25)
Except: RPC believes this action, coupled with additional signed distribution contracts and hiring of a Director of Oncology, will enable RPC to meet its FY2010 forecast of approximately $7.6 million in Onko-Sure cancer test kit sales.
Since the runup in April, we have been reporting at our sister site www.greenbackers.com that the stock has been displaying a solid basing pattern at a buck with several sharp bounces off of it.
Other recent news of interest:
- Radient Pharmaceuticals Announces Latest Developments in Its Onko-Sure Commercialization Plan for India; Company’s India-Based Partner Driving Government Backed General Cancer Screening ProgramMarketwire(Tue, Jun 15)
Book Value Per Share (mrq):
Bottom Line: Predictable. Accumulate for another bounc back abovce 1.25.
ANX among steepest declines this last qtr from 7, however it has been acting up some the last two weeks.
Jun 18: 1.97 0.14 (7.65%)
Just over a week ago it popped from 1.80 to 2.10 on a buy rec.
Coverage initiated on ADVENTRX Pharma by Caris & CompanyBriefing.com(Mon, Jun 7)
Want to point out trading very near cash and book.
Total Cash (mrq):
Total Cash Per Share (mrq):
Total Debt (mrq):
Total Debt/Equity (mrq):
Current Ratio (mrq):
Book Value Per Share (mrq):
Bottom Line: Debate weakness back at cash (1.93). Breaking 2 near term.
Lastly, want to make mention on Cell Therapeutics, Inc.(NasdaqCM: CTIC).
A couple weeks ago the stock saw significant news on a European deal.
Italian Medicines Agency Approves NerPharMa to Manufacture Cell Therapeutics’ Drug Pixantrone in European Union
PR Newswire (Mon, Jun 14)
The result was a pop to .57. It pulled back to .45 this week and is building off of it.
Other recent news that sparked trading interest
Cell Therapeutics Reports New Data Demonstrating That Complete Responses to Pixuvri Are Correlated With Prolonged Survival in Patients With Relapsed or Refractory Aggressive NHL
PR Newswire (Fri, Jun 11)
OPAXIO(TM) Phase II Study Results Confirm High Rate of Complete Response with Low Rate of Side Effects in Patients with Advanced Esophageal Cancer
PR Newswire (Mon, Jun 7)
Bottom Line: The news has been upbeat and frequent here. Look for a jump back above .50.